Navigation Links
Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
Date:5/16/2008

BALTIMORE, May 16 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has enrolled and randomized its first patient in a twelve-week Phase IIb trial with oral larazotide acetate, an inhibitor of intestinal barrier dysfunction, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while also testing components of a celiac disease activity rating index, a new patient reported outcomes instrument. "This is Alba's sixth human trial with larazotide acetate and highlights our efforts to improve the treatment of celiac disease and help the celiac community by raising the awareness of this important and neglected disease," stated Dr. Francisco Leon, Head of Clinical Research and Development at Alba. "Alba is committed to studying new treatment options for patients with celiac disease. By conducting this important pioneering clinical study we believe we can learn more about celiac disease and provide insights for physicians and celiac patients," stated Bruce Peacock, CEO of Alba. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Celiac Disease

Celiac disease is a lifelong T-cell mediated auto-immune disorder, which occurs in individuals who are genetically susceptible and is characterized by small intestinal inflammation, injury and intolerance to gluten. CD is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. People with CD cannot tolerate gluten proteins and have an inflammatory response to the gluten in wheat, barley and rye. This results in varying symptoms su
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
2. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Nile Therapeutics Reports 2008 First Quarter Financial Results
4. Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... The report provides basic information on ... and industry overview. This report also presents product ... is separated by regions, technology and applications. The ... client survey, marketing channels, industry development trend and ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... University researchers are finding ways to improve infrared photodetector ... systems, as well as used increasingly in commercial applications ... in a recent article in the journal ... how infrared photodetection can be done more effectively by ...
... LEXINGTON, Mass., Feb. 14, 2012 Avaxia Biologics, ... drugs that act locally within the gastrointestinal tract, ... million Series A angel-led financing.  Cherrystone Angels of ... from Beacon Angels, Boston Harbor Angels, Launchpad Venture ...
... PROVIDENCE, R.I., Feb. 14, 2012  Nabsys, Inc., a ... positional sequencing technology, today announced that data demonstrating ... DNA will be presented at the annual Advances ... 15 to 18, on Marco Island, Fla., and ...
Cached Biology Technology:New nano-material combinations produce leap in infrared technology 2New nano-material combinations produce leap in infrared technology 3Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 3Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 2Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 3
(Date:1/22/2015)... Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), ... general the State of Washington,s Department ... new enrollment and central issuance system for driver,s licenses and ... The project planning and development will start in January 2015, ...
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... Restoration International (SER) released its May 2008 Briefing ... & Biological Conservation within the Ecosystem Approach at ... the Parties held in Bonn, Germany, May 19-30, ... Ecosystem Approach, as developed by the CBD and ...
... and Technology (NIST) have reported* a new technique to ... centrifuges. Many potential applications for carbon nanotubes depend on ... the most important features of the new technique, say ... to produce industrial quantities of high-quality nanotubes. ...
... of shipments involving regulated radioactive materials used in medicine ... industry experts. Meeting in Rome this week at an ... the Mediterranean region that seeks to ease hardships for ... delivery of beneficial radiation sources. The shipment issues ...
Cached Biology News:Integrating restoration and conservation within the ecosystem approach 2Spin control: New technique sorts nanotubes by length 2Experts tackle shipment issues for beneficial radiation sources 2Experts tackle shipment issues for beneficial radiation sources 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Biology Products: